Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

D. Gross, Neil; M. Miller, David; I. Khushalani, Nikhil; Divi, Vasu; S. Ruiz, Emily; J. Lipson, Evan; Meier, Friedegund; B. Su, Yungpo; Swiecicki, Paul; Atlas, Jennifer; Geiger, J.L.; Hauschild, Axel; H. Choe, Jennifer; Hughes, Brett; Schadendorf, Dirk; Patel, Vishal; Homsi, Jade; M. Taube, Janis; M. Lim, Annette; Ferrarotto, Renata; L. Kaufman, Howard; Seebach, Frank; Lowy, Israel; Yoo, Suk‐Young; Mathias, Melissa; Fenech, Keilah; Han, Hyunsil; G. Fury, Matthew; Rischin, Danny

doi:10.1056/nejmoa2209813

Public

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

Published in New England Journal of Medicine • Sep 12, 2022

Authors:

Neil D. Gross

David M. Miller

Nikhil I. Khushalani

Abstract

BACKGROUND: In a pilot study involving patients with cutaneous squamous-cell carcinoma, a high percentage of patients had a pathological complete response with the use of two doses of neoadjuvant cemiplimab before surgery. Data from a phase 2 study are needed to confirm these findings. METHODS: We c...

Subject

Medicine

Stage (stratigraphy)

Basal cell

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!